Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

Cancer Type
Eye Cancer
Trial Phase
Phase II
18 to 99, Male and Female
Study Type
Protocol IDs
IMCgp100-202 (primary)
Study Sponsor
Immunocore Ltd


To evaluate the overall survival of HLA-A*0201 positive adult patients with previously

untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine,

ipilimumab, or pembrolizumab.


This Phase II study is designed to evaluate the safety and efficacy of IMCgp100 compared with

Investigator's Choice (dacarbazine, ipilimumab or pembrolizumab) in HLA-A*0201 positive adult

patients with advanced UM treated in the first line setting with no prior systemic or

liver-directed chemo-, radio- or immune-therapy administered in the advanced setting (prior

surgical resection of liver metastases and adjuvant systemic therapy are acceptable).

Comparison of the IMCgp100 efficacy results in this Phase II study will be made with the

concurrently randomized arm (Investigator's Choice) with a primary endpoint of overall

survival (OS) and secondary efficacy endpoints of progression-free survival (PFS), objective

response rate (ORR), duration of response (DOR), and disease control rate (DCR).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University

1365 Clifton Road NE
Building C
Atlanta, GA 30322

Georgia CORE


Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.